Abstract: Antibiotic resistance is increasing at a rate that far exceeds the pace of new development of drugs. Antimicrobial peptides, both synthetic and from natural sources, have raised interest as pathogens become resistant against conventional antibiotics. Indeed, one of the major strengths of this class of molecules is their ability to kill multidrug-resistant bacteria. Antimicrobial peptides are relatively small (6 to 100 aminoacids), amphipathic molecules of variable length, sequence and structure with activity against a wide range of microorganisms including bacteria, protozoa, yeast, fungi, viruses and even tumor cells. They usually act through relatively non-specific mechanisms resulting in membranolytic activity but they can also stimulate the innate immune response. Several peptides have already entered pre-clinical and clinical trials for the treatment of catheter site infections, cystic fibrosis, acne, wound healing and patients undergoing stem cell transplantation. We review the advantages of these molecules in clinical applications, their disadvantages including their low in vivo stability, high costs of production and the strategies for their discovery and optimization.
Introduction and biological activity
Antibiotic resistance has become a global public-health problem, thus it is imperative that new antibiotics continue to be developed.
Antimicrobial peptides (AMPs) are an evolutionarily conserved component of the innate immune response, which is the principal defence system for the majority of living or-ganisms, and are found among all classes of life ranging from prokaryotes to humans [1, 2] . They represent a new family of antibiotics that have stimulated research and clinical interest [3] as new therapeutic options for infections caused by multidrug-resistant bacteria. The diversity of AMPs discovered is so great that it is difficult to categorize them except broadly on the basis of their secondary structure [4, 5] . Basically, AMPs can be classified in four major classes: β-sheet, α-helical, loop and extended peptides [6] , with the first two classes being the most common in nature. In addition to the natural peptides, thousands of synthetic variants have been produced which also fall into these structural classes. A rich collection of all known AMPs can be found in the Antimicrobial Peptide Database (http://aps.unmc.edu/AP/main.php). The Antimicrobial Peptide Database offers an interface to predict the antimicrobial activity of any submitted sequence, based on a simple residue analysis and count method and some useful statistical information on peptides sequence, function and structure.
AMPs are generally defined as peptides of less than 100 amino acid residues with an overall positive charge (generally +2 to +9), imparted by the presence of multiple lysine and arginine residues and a substantial portion (≥30% or more) of hydrophobic residues. Currently, more than 800 AMPs with several different sequences have been isolated from a wide range of organisms. A list of some well-studied AMPs is reported in Table 1 . A common feature shared among the cationic AMPs is their ability to fold into amphipathic conformations, often induced by interaction with membranes or membrane mimics. Alongside their direct antimicrobial activities against Gram-positive and Gramnegative bacteria, these peptides play additional roles as antibiotics against fungi [7] and protozoa [8] with micromolar or submicromolar minimal inhibitory concentrations (MIC) [6] .
Magainins, magainin 2 and PGLa, are among the best studied AMPs. They are linear peptides that were originally isolated from the skin of the African frog Xenopus laevis. Magainins are α-helical ionophores that possess two important activities: a broad antimicrobial spectrum and an anti-endotoxin activity [9] . Moreover they have been shown to lyse hematopoietic tumor and solid tumor cells by targeting cell membrane via a nonreceptor pathway with little toxic effect on normal blood lymphocytes [10] . AMPs may also possess immunomodulatory activity when involved in the clearance of infection, including the promotion of wound healing [11] , they can act as chemokines and/or induce chemokine production, inhibiting lipopolysaccharide (LPS)-induced pro-inflammatory cytokine production and recruiting antigen-presenting cells, which can initiate responses by the adaptive immune system [12] . A number of AMPs such as defensins have multiple functions in host defense [13] . They are a highly complex group of 3-5 kDa open-ended cysteine-rich peptides widely distributed in nature and found both in vertebrates and invertebrates. On the basis of their size and pattern of disulfide bonding, mammalian defensins are classified into three classes: α-, β-and θ-defensins, with the majority of research focused on the first two classes. Depending on the species, α-and β-defensins are found in neutrophils, epithelial cells, certain macrophage populations and Paneth cells of the small intestine [14] . Human defensins can act as chemoattractants for mono-cytes [15, 16] , stimulating their TNF and IL-1 expression [17] , and they can enhance the expression of IL8 in lung epithelial cells [18] . Moreover, defensins could exert chemotactic activity not only towards nonspecific phagocytes but also towards cells engaged in adaptive immunity response [19] . Plant defensins are structurally related to defensins found in other organisms including humans. These AMPs are small (45-54 amino acids), highly basic cysteine-rich peptides that are apparently ubiquitous throughout the plant kingdom and play a fundamental role in defense against bacteria and fungi. To date, sequences of more than 80 different plant defensin genes from different plant species are available [20] .
The second large family of AMPs in mammals is represented by cathelicidins. They are AMPs bearing an amino-terminal cathepsin L inhibitor domain (cathelin). The C-terminal 37 domain of the only human cathelicidin h-CAP 18, LL-37, is an amphipathic, helical peptide that exerts broad antimicrobial activity [21] . LL-37 has been found to have additional defensive roles such as regulating the inflammatory response and chemo-attracting cells of the adaptive immune system to wound or infection sites, stimulation of angiogenesis and chemotaxis of neutrophils, monocytes and T-cells. LL-37 is found throughout the body: in epithelial cells of testis, gastrointestinal and respiratory tract, in skin and in leukocytes [21] .
AMPs such as mellitin and cecropin, isolated from bee venom and hemolymph of moths respectively, are capable of inhibiting cell-associated production of HIV-1 by suppressing HIV-1 gene expression [22] . A synthetic tachyplesin (an antimicrobial peptide present in leukocytes of the horseshoe crab Tachypleus tridentatus) conjugated to the integrin homing domain RGD showed to inhibit the proliferation of both cultured tumor and endothelial cells [23] alongside other AMPs, such as defensins [24] , cecropin [25] , lactoferricin [26] and lactoferrin [27] that showed a similar anti-tumor activity. The selective disruption shown by AMPs for cancer cell plasma membranes is primarily ascribed to the negative outer surface charge, imparted by the slightly higher levels of anionic phosphatidylserine (PS) [28] as compared to normal eukaryotic cells. Recent data supported this hypothesis showing that a number of human cancer cells were preferentially killed by NK-2, an AMP derived from an antibacterial effector protein from porcine NKand T-cells, showing a strong correlation with the amount of cell surface PS [29] . The presence of O-glycosylated mucines (high molecular weight glycoproteins) that create an additional negative charge on the cancer cell's surface may have an additional role in the selective cytotoxicity of the peptides [30] . If internalized inside eukaryotic cells, AMPs could interact with the mitochondrial membranes inducing membrane potential depolarization and tumoral cell death via the mitochondrial pathway of apoptosis [31] .
Certain AMPs have been shown to inhibit the replication of enveloped viruses such as influenza A virus [32] , vesicular stomatitis virus (VSV) and human immunodeficiency virus (HIV-1) [33, 34] . The generally accepted mechanism of antiviral action is a direct interaction of these peptides with the envelope of the virus, leading to permeation of the envelope and, eventually, lysis of the virus particle, analogous to the pore-formation model suggested for antibacterial activity. Other mechanisms for antiviral action have also been proposed: T22 ([(Tyr5,12,Lys7)-polyphemusin II]) a 18 amino acids peptide analogue of polyphemusin II, an AMP isolated from the hemocyte debris of American horseshoe crabs (Limulus polyphemus), was found to specifically inhibit the ability of T cell line-tropic HIV-1 to induce cell fusion [35] . It appears as though many peptides initially defined as "AMPs" have been shown to have several alternative functions in vivo.
A large amount of experimental work aiming to understand AMPs structure, peptidemembrane interactions and their relationships with the peptides' biological actions have been carried out reflecting the increasing interest in this area. In particular, Ramamoorthy et al. used specific membrane model systems and nuclear magnetic resonance (NMR) to characterize structure and dynamics of several AMPs such as pardaxins [36] [37] [38] , MSI-78 (Pexiganan) and MSI-594 synthetic magainin analogues [39, 40] , MSI-843 lipopeptide [41] , granulysin [42] , tachyplesin [43] and a cyclic peptide subtilosin A [44] . In particular, the studies on pardaxin [36, 38] have shown the role of cholesterol on inhibiting the membrane disruption and the role of the peptide on the formation of cholesterol-rich domains. Other studies on the carboxy-amide of pardaxin (P1a), have also observed the change in membrane disruption mechanism, from barrel-stave to carpet type, on membranes of varying composition [38] . It is likely that other AMPs acting through composition-dependent mechanisms could be isolated in the future since operating by more than one mechanism could represent an evolutionary advantage. A study on tachyplesin has shown the role of the Cys-Cys bond on structure, folding and function of the peptide in search of analogues with improved or adequate antimicrobial activity and cell selectivity. Since the absence of disulfide bonds could make an AMP easier and less expensive to produce, the study provides useful findings in designing AMPs for pharmaceutical applications that retain a significant antimicrobial activity and are free from Cys residues [43] .
This review will be focused on the current knowledge of AMPs, with emphasis on the mechanism of action, their applicability as therapeutic agents and several strategies for their isolation and optimization.
Mode of action
The molecular mechanism of membrane permeation and disruption of AMPs depends on a number of parameters such as the amino acid sequence, membrane lipids and peptide concentration. Until now, the majority of experiments have focused primarily on the interaction of cationic peptides with model membrane systems. Additional studies have also been conducted on whole microbial cells predominantly utilizing membrane potential sensitive dyes and fluorescently labeled peptides. These studies have indicated that all AMPs interact with membranes and tend to divide peptides into two mechanistic classes: 1) membrane disruptive (barrel stave, toroidal, carpet and micellar aggregate models) and 2) non-membrane disruptive (intracellular targets) [45] . A number of models for antimicrobial peptide membrane permeabilization have been proposed even if it should be stated that there is not universal consensus among investigators in this regard.
Bacterial membranes are negatively charged with lipids bearing phospholipid headgroups such as phosphatidylglycerol (PG), cardiolipin (CL), or phosphatidylserine (PS).
Table 1
Description of some well-studied AMPs originating from a wide range of sources, selected as representative examples of their structural class.
On the contrary, mammalian membranes are enriched in zwitterionic phospholipids (neutral in net charge) as phosphatidylethanolamine (PE), phosphatidylcholine (PC), or sphingomyelin (SM) [46] . Moreover, the presence of cholesterol, a major constituent of mammalian cellular membranes, can reduce the activity of AMPs stabilizing the lipid bilayer or by directly interacting and neutralizing them [47] . Composition likely provides an important determinant by which AMPs selectively target microbial versus host membranes.
The mechanism of action of AMPs on Gram-negative bacteria will be discussed in this review since it has been largely studied. An overview of the interaction of peptide with a Gram-negative bacterial envelope is shown in Figure 1 . The initial association of peptides with the bacterial membrane occurs through electrostatic interactions between the cationic peptide and anionic lipopolysaccharide, a major Gram-negative bacterial component that is stabilized by interactions between divalent cations such as Mg 2+ and Ca 2+ [48] . Removal of these ions or their displacement by cationic AMPs facilitates the formation of destabilized areas through which the peptide translocates the outer membrane in a process termed self-promoted uptake [49] . At this point, AMPs associate with the outer monolayer of the cytoplasmic membrane inserting into the membrane interface and then are proposed to create micelle-like aggregates with associated water, leading to a disruptive overall effect. In a mechanism non-disruptive for the membrane, the AMP molecules can also pass through and dissociate from the membrane, binding to cellular polyanions such as DNA and RNA or inhibiting other intracellular targets [48] . In a mechanism non-disruptive for the membrane, the AMP molecules can also pass through and dissociate from the membrane, binding to cellular polyanions such as DNA and RNA or inhibiting other intracellular targets [48] . Fig. 1 The proposed mechanism of action for antimicrobial peptides in Gram-negative bacteria. AMPs are proposed to associate with the negatively charged surface of the outer membrane by either neutralizing the charge over a patch of the outer membrane or by strongly interacting to the divalent cation binding sites on LPS. The listed models explaining the mechanisms of membrane permebilization include: (A) carpet, (B) barrelstave, (C) wormhole or toroidal, and (D) aggregate channel. The net effect of A to D is that some monomers will be translocated into the cytoplasm and can dissociate from the membrane and bind to cellular polyanions such as DNA and RNA, inhibit enzymatic activity such as protein synthesis or chaperone assisted protein folding. Lantibiotics such as nisin can inhibit the transglycosylation of lipid II, which is necessary for the synthesis of peptidoglican.
The several mechanistic models introduced in Figure 1 (the "barrel-stave", "carpet", "wormhole or toroidal" and "aggregate channel" models) are described in detail below.
Permeabilization mechanisms
Some peptides may act against microorganisms through a relatively diffuse manner, termed the "carpet mechanism" that involves initial peptide binding to the membrane surface to form high density clusters that cover the surface ( Figure 1A) . It is generally accepted that peptide activity is not detergent-like [50] occurring by phospholipid displacement that changes in membrane fluidity and/or reductions in membrane barrier properties that subsequently lead to membrane disruption. As in other models, peptides initially bind to the membrane mainly via electrostatic interactions, carpeting the phospholipid bilayer [51] . When a threshold peptide density is reached, the membrane is subjected to significant curvature strain leading to disruption. From this perspective, membrane dissolution occurs in a dispersion-like manner that does not involve channel formation, and peptides do not necessarily insert into the hydrophobic membrane core. For example, polarized attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy studies on cecropin P1, a peptide derived from moth hemolymph indicates that this peptide initially orients parallel to the membrane and does not enter the hydrophobic environment thereby destabilizing phospholipid packing. Yet, this peptide is an efficient antimicrobial agent that causes membrane disruption due to a concentrated layer of peptide monomers on the surface [46, 52] .
The barrel stave mechanism is proposed for a selected group of peptides. This model involves the perpendicular insertion and aggregation of a relatively small number of individual peptides (or peptide complexes) also referred as staves in a barrel-like ring inside the membrane leading to a transmembrane pore or channel with a cylindrical structure ( Figure 1B ). In this mechanism, the hydrophobic surfaces of α-helical or β-sheet peptides face outward, toward the acyl chains of the membrane, whereas the hydrophilic surfaces form the pore lining [53] . The initial step in a barrel-stave pore formation involves peptide binding at the membrane surface, most likely as monomers and after a conformational phase transition, the hydrophobic portion of the peptide is inserted into the membrane to an extent corresponding to the hydrophobicity of the membrane outer leaflet while electrostatic interactions facilitates this process. When bound peptide reaches a threshold concentration, peptide monomers self-aggregate and insert deeper into the hydrophobic membrane core. Aggregation allows for a minimal exposure of the peptide hydrophilic residues to the hydrophobic membrane interior, as the peptides adopt a transmembrane configuration. The pore is a dynamic structure and the continued recruitment or lose of peptide monomers results in a relatively polydisperse pore size. A minimal length of ∼22 amino acids is required to transverse the lipid bilayers with α-helical peptides, or ∼8 amino acids if the peptide adopts a β-sheeted structure [54] . Alamethicin (Alm) is a well-studied example of a peptide that inserts and aggregates within cell membranes to form conducting channels [55] [56] [57] . Alamethicin-induced membrane conductance has been measured to proceed as a pattern of multistate conductance levels. This finding suggests the existence of pores with openings of various diameters (2-3Å), corresponding to channels composed of 4-6 transmembrane-spanning peptides. However, there remain relatively few peptides for which there is compelling evidence of a barrel-stave mechanism, despite this model having been proposed more than a decade ago.
More recent studies often support the toroidal pore model [56, 58] . This model is an extension of the transmembrane helical bundle in which the pores are lined with peptides and lipids. A number of studies have been devoted to the elucidation of both the structure of these peptide pores and the process of pore formation, mainly by the groups of Matsuzaki [59] and Huang [56] . A pore structure that involves lipids and peptides was first proposed by Matsuzaki et al. [60] based on the observation that magainin 2 induces rapid lipid flip-flop coupled with pore formation. The presence of negatively charged phospholipids in the pore-lining reduces the repulsive interactions due to the high positive density of charges of the peptides [61] and could explain the modulation in ion selectivity due to alterations of membrane composition [62] . The model postulates that peptide and lipid together form well-defined pores, with the membrane also curving inward to form a hole with the head groups facing towards the center of the pore while the peptides line this hole. Although the formation of a formal toroidal channel has not actually been demonstrated, the model predicts that the membrane will exhibit positive curvature strain ( Figure 1C ). The formation of the toroidal pore and translocation of the peptide depends on a critical peptide-lipid ratio. An intolerable increase in peptide concentration would reduce the stability of the pore as a result of enhanced electrostatic repulsion (Coulomb energy) between the positive charged side chains [63] . A study representing a step forward in understanding self-association in determing magainin activity and selectivity has been performed by the group of Ramamoorthy using NMR experiments on two synthetic variants of magainins (MSI-78 and MSI-594) solubilized in dodecylphosphocholine (DPC) micelles. The results supported the α-helical conformation for both peptides but different tendencies to self associate: dimerization for MSI-78 (antiparallel dimer formation) and a pronounced conformational heterogeneity for MSI-594. For MSI-78, dimerization screens the hydrophobic residues reducing the affinity for mammalian membranes which contain zwitterionic lipids in the outer leaflet, while exposing positive charges. MSI-78 propensity to form stable dimers make it more selective and active toward the negatively charged bacterial membranes if compared to MSI-594 [39] . Examples of AMPs, other than magainins, that are proposed to form this type of pore include mellitin and LL-37 [56, [64] [65] [66] .
The barrel stave, the carpet and the toroidal models predict that the killing activity of AMPs occurs due to perturbation of membrane integrity. However, several studies indicate that permeabilization is necessary but may not be enough to explain antimicrobial activity [67] . Planar lipid bilayer model studies showed that transient conductance events indicative of pore formation were only seen at high concentrations of peptides and high transmembrane voltages [3] , with little correlation between their magnitude and the bactericidal potency. In fact, some peptides, e.g. Gramicidin S, caused maximal membrane depolarization at a concentration well below their minimal inhibitory concentrations indicating that membrane depolarization alone is not necessarily the crucial event in the killing of microorganisms. To overcome this discrepancy, the aggregate channel model was proposed [48] . After binding to the phospholipid head groups, the peptides insert into the membrane and then cluster into unstructured aggregates allowing the dynamic formation of pores that span the membrane for short periods ( Figure 1D ). AMPs can also enter the intracellular space through this mechanism. Once inside, the peptides home in on their intracellular targets to exert their killing activities [3] . NMR studies with indolicidin revealed an interesting fold, comprised of a hydrophobic core flanked by two positively charged regions, suggesting the insertion into the hydrophobic core of the membrane and formation of channel aggregates [68] .
Alternative mechanism of action: intracellular targets
Permeabilization, per se, does not invariably result in bacterial death. Thus, although AMPs interact with microbial cell membranes, creating pores that lead both to leakage of ions and metabolites and depolarization as described above, it is likely that these effects contribute to mechanisms by which AMPs exert their effects. However, a mounting body of evidence supports additional or complementary mechanisms. Several studies investigated the relationship between bacterial membrane permeabilization and cell death revealing that cell killing may proceed with relatively little membrane disruption and suggesting that AMPs may interact with putative key intracellular targets.
Several studies with different AMPs have shown that all-L and all-D enantiomers are not of equal activity pointing to a stereo-specific interaction [69] . For example, the all-D isomers of apidaecin [70] and drosocin [71] are no longer active. Indolicidin was proposed to inhibit DNA synthesis leading to filamentation in Escherichia coli [72] . Some AMPs were found to interfere with the metabolic processes of microbes, an example is the glycine-rich attacins that showed to block the transcription of the omp gene in E. coli [73] , whereas magainins and cecropins induce selective transcription of its stress-related genes micF and osmY at non-bactericidal concentrations [74] . PR-39, a porcine proline/arginine-rich antimicrobial peptide, is able to bind the cell membrane of E. coli without affecting its integrity [75] and kill bacteria by blocking both DNA and protein synthesis [76] . Buforin II, a histone H2A-derived antimicrobial peptide originally isolated from the Asian toad, inhibits the cellular functions of E. coli by binding to DNA and RNA after penetrating the cell membranes [77] . Two bovine bactenecins, Bac5 and Bac7, inhibit protein and RNA synthesis of E. coli and Klebsiella pneumoniae and inhibit their respiration inducing a drop in ATP content [78] . The class of short, proline-rich antimicrobial peptides secreted by insects, such as pyrrhocoricin, apidaecin, and drosocin, are thought to kill bacteria by entering cells and inhibiting the molecular chaperone DnaK [79] . DnaK is a 70-kDa molecular chaperone that functions co-translationally and post-translationally to promote protein folding and to inhibit the formation of toxic protein aggregates. The killing of bacteria and DnaK binding are related events, as an inactive pyrrhocoricin analogue made of all -D-amino acids failed to bind to DnaK. These inhibitors could represent an important new class of antimicrobial agents since they demonstrated to selectively bind to the prokaryotic but not to the eukaryotic chaperone [80] .
Alternative mechanisms of action may act independently or synergistically with membrane permeabilization [3] . Nevertheless, the interaction with the bacterial cell membrane appears to be the killing mechanism of the vast majority of AMPs [81] .
Potential as therapeutics
AMPs have many of the desirable features of a novel antibiotic class [82] and can complement conventional antibiotic therapy. Moreover, they show synergy with classical antibiotics, neutralize endotoxin and are active in animal models. Minimal inhibitory concentration (MIC) and minimal bactericidal concentrations (MBC) often coincide (less than a two-fold difference), indicating that killing is generally the highly desirable bactericidal mode of action. Most pharmaceutical effort has been devoted to the development of topically applied agents, such as the magainin 2 analogue Pexiganan [83] , largely because of the relative safety of topical therapy and the uncertainty surrounding the long-term toxicology of any new class of drug administered systemically. The main hurdles that have impeded the development of AMPs as systemic therapeutics include the experience that many of the naturally occurring peptides (such as magainins), although active in vitro, are effective in animal models of infection only at very high doses. The proximity of these doses to the toxic doses of the peptide reflects an unacceptable margin of safety that could justify their use. Moreover, since AMPs share features with eukaryotic nuclear localization signal peptides and are able to translocate into cells, they are responsible for more subtle toxicities, including apoptosis, mast-cell degranulation or extracellular DNA transfer, and need further studies [82] relative to their use in systemic therapy. AMPs now involved in pharmaceutical development are shown in Table 2 . Pexiganan (Magainin Pharmaceuticals, since renamed Gaenera, USA), a 22-aminoacid analogue of magainin 2, was the first antimicrobial peptide to undergo commercial development as an antibiotic cream for the topical treatment of diabetic foot ulcers named Locilex T M . In 1999 FDA approval was denied because Pexiganan showed insufficient evidence of efficacy despite unanimous agreement about the drug's performance in phase II trials [84] at which stage most drugs (60-70%) fail due to low efficacy. Iseganan (Intrabioitcs Pharmaceuticals, USA), a pig protegrin-based peptide, in clinical trials failed to prevent or reduce oral mucositis in patients receiving radiotherapy for head-and-neck malignancy [85] and to prevent ventilator-associated pneumonia. The most advanced antimicrobial peptides are currently two indolicidin-based peptide variants MX-226 (Omiganan pentahydrochloride 1% gel) and MX-594AN developed by Migenix (Canada). MX-226 is a topical antibiotic for the prevention of catheter-related infections. In August 2005, Migenix, in collaboration with Cadence Pharmaceuticals, initiated a confirmatory Phase III clinical trial with a primary endpoint being the reduction of local catheter site infections. MX-594AN is a novel, topical antibiotic for the treatment of acne vulgaris (Phase IIb completed in 2003) licensed to Cutanea Life Sciences in late 2005. Xoma (USA) has two peptides in its pipeline derived from bactericidal/permeability-increasing protein (BPI), a human host-defense protein that is one of the body's early lines of defense against invading mi-croorganisms, known for its ability to kill bacteria and to neutralize the action of LPS. XOMA 629 showed activity against Propionibacterium acnes and other skin flora but preliminary Phase II trial results were inconclusive as to clinical benefit of XOMA 629 compared to vehicle gel (placebo) [86] . Additional studies are ongoing to explore this new approach to treat topical and systemic infections such as chemotherapyinduced neutropenia and hospital pneumonia. P113 (developed by Periodontix, USA, then acquired by Demegen, USA) is a 12-amino-acid cationic peptide based on histatins, naturally occurring AMPs in the saliva [86] that demonstrated excellent in vitro activity against Candida albicans and common Gram-positive and Gram-negative pathogens. Demegen licensed P113 to Pacgen (Canada) for treatment as a mouth rinse for oral candidiasis in HIV patients (approval for Phase I/II clinical study received on March 2006). P113 with D-amino acids gave rise to P113D, a compound that demonstrated to be less amenable to enzymatic degradation and maintained the antimicrobial activity of the parent compound is planned to enter clinical trials as an inhalation treatment for Pseudomonas aeruginosa lung infections in cystic fibrosis patients. AM-Pharma (The Netherlands) is focused on the development of lactoferricin-based peptides (11-mer peptide from the N-terminus of human lactoferricin, hLF-11) for the prevention of infections in patients undergoing hematopoietic stem-cells transplantation (Phase I completed). In September 2003, the FDA approved Daptomycin, a cyclic anionic lipopeptide antibiotic, for the treatment of complicated skin and skin-structure infections. The compound was originally discovered by researchers at Eli Lilly & Company in the 1980s, who designated the compound LY 146032. Due to the adverse effects on skeletal muscle Lilly ceased development. The rights to LY 146032 were subsequently acquired by Cubist Pharmaceuticals in 1997, which subsequently marketed the drug under the trade name CUBICIN R . Daptomycin is active against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant enterococci (GRE)), staphylococci (including methicillin-resistant S. aureus), streptococci and corynebacteria. Interestingly, its function is dependent on calcium (Ca 2+ ). Indeed, the association of Ca 2+ with Daptomycin permits it to interact with bacterial membranes with effects that are similar to those of the cationic AMPs. Polymyxins (polymyxin B and polymyxin E) are old cyclic cationic lipopeptides (they were discovered in 1947 entered into clinical use in 1960) that are rapidly bactericidal against Gram-negative bacteria: Acinetobacter, P. aeruginosa, Klebsiella, Enterobacter, E. coli, Citrobacter, Morganella, Haemophilus influenzae and some strains of Stenotrophomonas maltophilia [87, 88] . Polymyxins have been used for topical application with cultured skin on burns, for operative wound irrigation, for selective decontamination of the digestive tract, for superficial eye infections and for the prevention of minor wound infections. Polymyxins are most often combined with other agents to provide broad-spectrum antibiotics, as with the classical neomycin sulfate and bacitracin combination [89] . Unfortunately, polymyxins are too toxic (mainly nephrotoxicity, neuromuscular blockage and neurotoxicity) at clinically used doses to be used systematically [90] . As almost no novel agents have been introduced to combat multiple-antibiotic-resistant organisms, clinicians maybe forced to rediscover colistin and colistimethate (colistin methanesulphonate sodium, colistin sulphomethate sodium), a pro-drug derivative used systematically in intravenous infections of cystic fibrosis patients [90] . Given the concern for potential toxicity, the use of colistin and polymyxin B should be viewed as a treatment of last resort for patients who have serious infections caused by multidrug-resistant Gram-negative pathogens for which no other therapeutic options exist. However, the significant recent increase in the data gathered on polymyxins, focusing on their chemistry, activity, mechanism of action, toxicity, pharmacokinetic and optimum dosing strategies have led to the conclusion that these molecules have a better therapeutic index than was reported in old studies.
Several companies are conducting preclinical studies on AMPs. HelixBiomedix (USA) is developing an array of AMPs within several pharmaceutical programs ranging from topical anti-infective, wound healing and cystic fibrosis. Lytix Biopharma (Norway) is developing ultra-broad spectrum synthetic antimicrobial peptidomimetics (SAMPs TM ), effective against bacteria (including MRSA, methicillin resistant staphylococcus aureus) as well as fungi. SB006 and its derivatives are developed by SpiderBiotech (Italy). These molecules are tetrabranched synthetic peptides isolated by phage-display selection that show potent, protease-stable activity against Gram-negative, multidrug resistant clinical isolates [91] . Preclinical testing has shown that SB006 has a good safety profile and activity in several murine models of infection (unpublished data). PepTx (USA), an early stage pharmaceutical company, is developing preclinical compounds (PTXseries) based on β-sheet-forming peptide 33mers [92] originally designed by incorporating β-conformation stabilizing residues from the β-sheet domains of α-chemokines and functionally important residues from the β-sheet domain of human neutrophil bactericidal protein (BPI), PTX002 and its derivatives showed a broad spectrum of antimicrobial (Gram-negative bacteria in the nanomolar range and Gram-positive bacteria in the submicromolar range) and anti-endotoxin activity. Lantibiotics are a unique class of peptide antibiotics produced by Gram-positive bacteria. They are highly modified peptides rich in lanthionines, a nonproteinogenic aminoacid composes of two alanine residues that are crosslinked on their β-carbon atoms by a thioether linkage, combining the beneficial biological interactions and versatility of peptides with desirable pharmaceutical properties such as stability in the systemic circulation. Novacta Biosystems (England) is exploiting its innovative technological platform to develop optimized analogues of the lantibiotic Mersacidin as antibacterial agents against Gram-positive infections using a biosynthetic engineering approach, which will allow the primary amino acid sequence of the molecule to be extensively modified. The first defensin ever found in fungi, Plectasin, was discovered by a team from Denmark-based biotech company Novozymes and researchers from Georgetown University Medical Center and the David Geffen School of Medicine at UCLA in 2002 from a fungus, Pseudoplectania nigrella, that grows on the shady floors of northEuropean pine forests. Plectasin showed to be active at rates comparable to penicillin and vancomycin against S. pneumoniae, a bacterium responsible for a lot of diseases, including community-acquired pneumonia, sepsis and otitis media. Plectasin may represent the first of a powerful new class of antibiotics and antivirals and is currently under preclinical development [93] .
The broad antimicrobial spectrum of AMPs positions them for several other applications such as 'chemical condoms' to limit the spread of sexually transmitted diseases or imaging probes for bacterial and fungal infections, exploiting their affinity for microbial membranes [94] . Moreover, AMPs can enhance the potency of existing antibiotics in vivo, probably by facilitating access of antibiotics into the bacterial cell resulting in a synergic effect [95] . The successful demonstration that amphiphilic peptides covalently bonded to a water-insoluble resin retain antimicrobial activity [96] led to the suggestion of their use in the area of therapeutic medical devices such as intravenous catheters.
For infections with viruses or parasites that can hide in the host cells, dermaseptin peptides were shown to be active toward human erythrocytes infected by the malaria parasite Plasmodium falciparum [97] . Novel formulations and delivery systems may also be necessary in the future to modulate the action of AMPs with a low therapeutic index. In the past, an encouraging result has been obtained in an animal model for fungal infection, where the high cytotoxicity of indolicidin for host cells was overcome by administration of liposomally encapsulated material [98] . A revolutionary alternative in exploiting the potential of AMPs is described in a recent work by Raqib et al. [99] where they propose the use of sodium butyrate in the treatment of shigellosis, an infection of the gastrointestinal tract by bacteria of the genus Shigella, in an experimental infection in rabbits. This study led to the hypothesis that butyrate improves the outcome in shigellosis as a direct consequence of the LL-37 induction after the interaction of butyrate with rectal lumen.
Multi-drug resistance (MDR) is the major mechanism of drug resistance in malignant tumour cells, most commonly arising from the over-expression of P-glycoprotein, a membrane-bound efflux pump that actively removes many conventional anticancer drugs [100] . A few AMPs were found to be cytotoxic against MDR cancer cells [101] and to have minimized side effects when compared to other chemotherapeutic agents that are currently available [100] . Morevoer, AMPs have other important advantages: they kill cancer cells rapidly, are unaffected by classical chemotherapy resistance mutations, do not easily select chemotherapy-resistant variants, show synergy with classical chemotherapy (e.g. doxorubicin, etoposite, cisplatin), destroy primary tumors and pre-vent metastases [102] . In addition, due to their mechanism of action, AMPs are independent of cell proliferation and can be employed to destroy nondividing (dormant) tumor cells. To be clinically used, these peptides need to combine high and specific anticancer activity with stability in serum. Several studies addressed these issues by targeting them to specific sites using homing domains [23] , by vector-mediated delivery of genes encoding AMPs into tumor cells [103] or by designing and synthesizing derivatives of natural AMPs through optimization of amphipathicity, deletions and/or substitutions of amino acids [100] . Table 2 Commercial development of antimicrobial peptides.
Limitation as therapeutics

Cost aspects
The principal reason why the pharmaceutical industry has been reluctant to promote the clinical use of this class of antibacteral therapeutics is the high production cost of peptides. The cost price of synthetic peptides is five to twenty times as high as that of conventional antibiotics. As a typical example, for the treatment of infections with the currently known AMPs about 1 mg/kg of body weight per day per patient would be necessary, with a cost of about $50-400 per gram [104] far too expensive for everyday usage in less developed countries. Despite this drawback, the most popular example of a peptidebased drug produced in multi-tons is the T-20 peptide (Fuzeon, Roche), which is the first HIV fusion-inhibitor peptide produced at such scale by a combination of solid phase and solution phase methodologies. The decision of Roche to go fully synthetic, instead of doing the 26-mer peptide recombinantly, and the following massive investment lowered the cost of all synthesis reagents, making industrial peptide synthesis more feasible. In general, the demand for higher quality peptides, the growing popularity of microwavebased peptide synthesis technology, and innovative strategies to enhance delivery and bioavailability of peptide drugs, are driving a radical improvement in production efficiency. The future is likely to be a landscape where pharma companies will increasingly move peptide drugs through their pipelines into late-stage development and where it will be possible to produce cost effective, high quality peptides.
One of the cheapest alternatives to synthetic peptides is production by recombinant expression methods using microorganisms that are resistant to the produced peptide antibiotic. Plectasin, the first fungal defensin with an interesting therapeutic potential, can be produced in a fungal expression system effectively and at high yields, the same system is currently used for industrial scale production of other proteins by Novozyme [93] . Although the costs may be lowered by a factor hundred, we must not underestimate the technical difficulties in producing large amounts of peptides. At the current production efficiency, for each 100 kg of recombinant peptide one million liters of fermentation mixture will be necessary [5] . This is acceptable for the production of proteins with a high specific activity, for instance hormones or recombinant vaccines, while it could be not economically feasible, not for the ton-scale production of AMPs. One of the most successful and efficient method for peptide production in an E. coli expression system has been already described [105] . A fusion protein containing an antimicrobial peptide, designated P2, at its carboxy terminus and bovine prochymosin at its amino terminus was genetically engineered. Bovine prochymosin was chosen as the fusion partner because of its complete insolubility and host protective activity from trom the toxic effect of P2 peptide. The choice of the fusion partner is generally critical for stability, yield and subsequent purification steps. As with many protein production methods, the production of AMPs by recombinant means for large-scale production could be an economically viable and promising alternative.
Antimicrobial peptide resistance
Unlike conventional antibiotics which microbes readily circumvent, it has been claimed that acquisition of resistance by a sensitive microbial strain against AMPs is surprisingly improbable due to the deep changes in membrane structure that would be needed to confer effective resistance [1] , their great diversity and the fact that AMPs have remained effective against bacterial infections for at least 10 8 years. Anyway, certain microbial pathogens are inherently more resistant to AMPs due to stable structural or functional properties or pathogenesis strategies. For example, resistant species of genera such as Morganella and Serratia express an outer membrane that lacks the appropriate density of acidic lipids to provide peptide-binding sites. Other resistant species, such as Porphyromonas gingivalis, secrete digestive proteases that destroy peptides [1] . In many species of Gram-negative bacteria, the charge on the outer membrane is modulated by the PhoPQ regulon, a two-component system that uses a sensor (PhoQ) and an intracellular effector (PhoP) [106] . Under potentially lethal stress conditions, the PhoP/PhoQ regulon affects antimicrobial peptide sensitivity through modulation of the PmrA regulon, which controls a bank of genes that mediate decoration of the outer membrane with the positively charged moieties of ethanolamine and 4-aminoarabinose [107] yielding global protein, phospholipid, and lipopolysaccharide modifications. Other virulent bacteria rely upon elaboration of a capsule as a means of adherence to tissue or avoidance of opsonization and phagocytosis such as the highly anionic capsular exopolysaccharide produced by virulent strains of P. aeruginosa [108] .
Attempts at inducing Pexiganan resistance in E. coli and S. aureus by chemical mutagenesis have been up to now unsuccessful. Anyway, population models of the evolutionary genetics of resistance have cast doubt on this claim. A very recent study has documented the experimental evolution of resistance to Pexiganan through continued selection in the laboratory. In this selection experiment, 22/24 lineages of E. coli and P. fluorescens independently evolved heritable mechanisms of resistance to Pexiganan when propagated in medium supplemented with this antimicrobial peptide for 600-700 generations [109] . The study demonstrated for the first time that resistance can evolve rapidly whenever bacterial populations are consistently exposed to elevated levels of AMPs. Even if the study raise several questions about the safety in developing and introducing AMPs in clinical practice, we must take into consideration that the conditions experienced in nature by bacteria are quite different and, at the moment, we cannot predict the time-scale required for the appearance of resistant pathogens.
Susceptibility to proteolysis
Peptides are relatively sensitive toward proteolytic degradation. The rapid clearance of peptides and unfavorable pharmacokinetics, due to proteolytic degradation, may severely restrict their applicability. In this context, it is noteworthy that clinical trials of peptide therapeutics have been generally focused on topical applications [5] . It has been suggested that complexation with negatively charged or lipophilic proteins may either facilitate clearance from the circulation [67] or protect AMPs against excessive proteolytic breakdown in vivo [110] even if it remains unclear to which extent complexation is a beneficiary effect for activity in vivo. To increase peptide half-life, many strategies involving several formulations, ways of administration and different levels of chemical modification are possible [111, 112] . The introduction of D-amino acids (whenever their mode of action doesn't require specific interaction with chiral targets), amidation at the N-terminus, nonnatural amino acids, and peptide cyclization are the most common strategies to increase peptide stability. The peptaibols for instance, a family of peptides characterized by short chain lengths (≤20 residues), C-terminal alcohol residues and high levels of non-standard amino acids, are quite resistant against proteolysis because they contain high levels of non-standard amino acids, principally α-amino-isobutyric acid, isovaleric acid (Iva) and the amino acid hydroxyproline (Hyp) [113] . Other uncommon amino acids can also be inserted to prevent binding to the active sites of proteolytic enzymes [114] or the peptide bonds may be modified in such a way that proteolytic enzymes can no longer cleave them, e.g. by alkylation of the nitrogen atoms [115] . Since there are few studies about pharmacokinetics of AMPs and the effects of all the above-mentioned modifications, considerable additional research on these issues is urgently needed.
Optimization strategies and high throughput screening of AMPs
While it is generally easy to design AMPs endowed with bactericidal activity using a mixture of positive charged and hydrophobic aminoacids, it has been proven to be difficult to improve other features such as in vivo stability, salt sensitivity and toxicity in view of their clinical applications.
In an attempt to improve microbicidal activity of a selected peptide, general optimization strategies may be followed including cyclization [116] , introduction of fluorine atoms or trifluoromethyl groups [117] , increase of positive charge or hydrophobicity [118] or improving segregation of polar and hydrophobic residue starting from an helical projection [119] . Recent studies have investigated the effect of different basic residues on peptide antibacterial activity and cell selectivity [120] . The primary amine of Lys interacts less electrostatically with zwitterionic phospholipids than the guanidinium group of Arg, suggesting that Arg-to-Lys substitution would increase selectivity against negatively charged phospholipids of bacterial membranes and cause the peptide to be less lytic to erythrocytes. All the findings suggest that the activity of AMPs is determined by a subtle combination of factors such as sequence, hydrophobicity and position of cationic residue. At the same time, a large number of studies have attempted to establish more precise quantitative structure-activity relationship (QSAR) between the primary sequence of AMPs and their activity toward selected microorganisms. Unfortunately, a general statement is almost impossible to obtain due to the complexity of the target (LPS and cell membranes) and the mechanism of action lacking a defined target. However, since the peptides are amenable to extensive chemical modification, several design strategies have been pursued by several groups with interesting results. One of the most classical approaches is the synthesis of combinatorial libraries built around an existing 18-mer lytic peptide composed of leucine and lysine residues and on a deconvolution strategy directed toward activity specificity [121] . This approach allows measuring the effect of different chemical composition and properties of bacterial, fungal and mammalian cell membranes on the induced conformations of peptides using CD spectroscopy and get insights into the physical and chemical factors that are important for membrane targeting. Many studies have shown that the amphipathic structure is a key factor for the biological function of AMP rather than the secondary structure. In another interesting approach [122] the effect of the covalent attachment of aliphatic acids with different lengths (10, 12, 14 and 16) to the N-terminus of a biologically inactive peptide have been evaluated. The data revealed that these modifications generally endowed the resulting lipopeptides with lytic activity while the selectivity against bacteria, fungi and human erythrocytes was influenced by the length of the fatty acid chain. The results suggested that working solely on the hydrophobic element of an AMP without mutating the primary sequence can be an effective strategy in the development of new lipopeptides with increased activity and, maybe, a better pharmacokinetic profile and resistance to proteases. To improve the antimicrobial profile of a peptide Otvos et al. [123] synthesized chimeric dimers in which pyrrhocoricin's potent DnaK-binding domain was connected to drosocin's superior cell penetrating module obtaining a new class of antimicrobials that kill bacteria with a combination of DnaK inhibition and membrane disintegration. The first successful creation of a synthetic, target-specific antimicrobial peptide has been reported by Eckert et al. [124] . A rationally designed Pseudomonas-specific targeting moiety (KH), functionally analogous to the targeting domain found in nisin, had been added to a general killing AMP (novispirin G10). The targeting domain KH, selectively delivered the killing domain (G10) to several Pseudomonas spp. resulting in an overall enhancement in killing kinetics and selectivity.
The rational design of new AMPs could be performed using a linguistic model [125] . This approach consists of treating the peptide sequence as a formal language and building a set of regular grammars to describe this language and create new, unnatural sequences where each amino-acid is analogous to words in a sentence. To find a set of regular grammars a Teiresias algorithm, a tool for the discovery of rigid patterns (motifs) in biological sequences, can be applied on a set of natural AMP sequences [126] . Overlapping grammars describing common arrangement of aminoacids can be put together to create new 20-mer sequences that correspond to the antimicrobial syntax. Designed sequences are scored and filtered to reduce redundancy and similarity to natural AMPs and then experimentally tested on various bacteria. Even if this approach is really original, it has some limitations. First, amino acid residues that are poorly conserved may be neglected with this approach. Second, the approach seems to be less useful when applied on large sequences. Hilpert et al. [127] set up a design strategy that seems to be a costand time-effective approach for the systemic investigation of pharmacologically relevant AMPs. The authors described a new technical approach based on the spot-synthesis on cellulose supports of 229 variants of Bac2A [128] , a small size, linear bovine bactenecin. Peptides can be cleaved from the support by ammonia gas, inserted and serially diluted into a microtiter plate and finally incubated with an indicator P. aeruginosa strain with a luciferase gene cassette incorporated as viability indicator. Sequence scrambling of Bac2A led to activities, as confirmed by minimal inhibitory concentration analysis, ranging from superior or equivalent to Bac2A to inactive. The system is estimated to allow the screening of 50,000 peptides per pipetting robot per year. Seldom has a method been developed to tap the potential of huge amount of genomic and proteomic data. A unique indexing method based on Fourier transformation (FT) to mine this rich source of data for the presence of peptides with potential antimicrobial activity has been developed by Nagarjan and co-workers [129] . FT methods has been extensively used in many bioinformatic applications, ranging from structural studies of proteins [130] to the analysis of genomic sequences to study periodicities in DNA sequences and detect probable coding regions [131] . All the different groups of peptide sequences were retrieved from the Antimicrobial Peptide Database and coded with numerical indexes based on their physicochemical properties such as hydrophobicity, polarity, charge, the presence of cysteines and amino acid distribution based on APD statistics. A method was established using a property-based sequence coding approach and tested mining randomly 10,000 different sequences of 16 residues in length and generating 3 hits that were submitted to APD's simple activity prediction tool to check and validate the prediction accuracy. This perspective could be impressive whenever the method could be tuned to include all the different classes of AMPs, virtually generating and data mining the whole peptide space for the AMPs.
The development of peptide phage libraries represents a major advancement in the discovery of new lead compounds for antibacterial therapy [132, 133] . An evaluation of phage-display-derived peptides as ligands for a broad range of bacterial enzymes was reported [134] . A series of well-characterized enzymes with diverse structures, functions and established biochemical assays were selected and a series of peptides that bound specifically to each target were isolated by phage display. These peptides were shown to be effective as inhibitors of enzymatic function in vitro [135] . Thus, isolated peptides can be used as inhibitors to evaluate the function of the enzyme or for antibiotic discovery efforts (i.e., as a lead compound for peptidomimetic design). Since it is well known that lipid A accounts for all the toxic effects of endotoxin [136] , in a recent study, Thomas et al. reported the results of obtaining lipid A binding peptides by biopanning of a repertoire of a random pentadecapeptide library displayed on the filamentous M-13 phage [137] . Twelve selected peptides were isolated and their primary structure revealed no consensus sequence between the peptides suggesting that the lipid A binding motif is not sequencespecific which is in accord with the high variability seen with the naturally occurring endotoxin binding peptides.
The use of peptides identified by phage display to inhibit the function of target proteins inside a bacterial cell has also been reported [138] . Peptides that bind to essential targets of known function were selected using phage display were subsequently expressed as fusions to glutathione-S-transferase (GST) under the control of a tightly regulated promoter and resulted in the inhibition of bacterial growth by inactivation of the specific target protein.
An interesting approach could be the investigation of a phage display system for the selection of peptides by biopanning of whole bacteria [91] . This could allow the selection, from a large peptide library, of bacterial membrane ligands with antimicrobial activity. Although its use for the identification of novel antimicrobial agents has not been fully exploited, the findings reported so far indicate that peptide phage libraries could play a promising role in the infectious disease area.
Dendrimeric peptides as novel antimicrobials
Multiple antigen peptide (MAP), consisting of a number of peptides covalently attached to a branching lysine core (Figure 2 ), was originally developed by Tam as a peptidic immunogen for preparation of antibody [139] . The in vitro and in vivo efficiency of dendrimeric peptides like MAPs is generally ascribed to their multimeric nature, which enables polyvalent interactions. In medical sciences, dendrimers are useful tools in several applications as an antibody mimics, drug transport vectors, anticancer agents, magnetic resonance imaging (MRI) contrast reagents, and so on [140] . In a recent study, Bracci et al. proposed the synthesis of bioactive peptides in dendrimeric form in order to increase their half-life, due to acquired resistance to protease and peptidase activity. Several experiments showed that the higher in vivo efficiency of dendrimeric with respect to monomeric peptides was additionally due to a pharmacokinetic advantage, such as different clearance, or resistance to peptidase and protease activity [141, 142] . This hypothesis was successfully verified by testing the stability of monomeric and dendrimeric peptides in human plasma and serum [143] . Recently, lysine cores have been used as synthetic scaffolds for the attachment of two to eight copies of a tetrapeptide R4 (RLYR) or an octapeptide R8 (RLYRKVYG) with the aim of producing antimicrobial dendrimers. Both R4 and R8 contained a combination of basic and lypophilic amino acids that have been found in protegrins and tachyplesins, natural peptides with antimicrobial activity. Dendrimeric effect was manifested by high potency in antimicrobial assays against 10 organisms in high-and low-salt conditions [144] . In other work, a series of low-generation dendrimeric peptides containing basic (lysine) and aromatic amino acids, was synthesized in an attempt to evaluate their antimicrobial potency [145] . All the dendrimeric peptides in which lysine was a starting and branching element expressed moderate activity against S. aureus NCTC 4163, and E. coli NCTC 8196.
Production of AMPs obtained by selecting a large 10-mer phage peptide library against whole E. coli cells was described by Pini et al. [91] . One selected peptide was isolated and synthesized both in monomeric and dendrimeric tetrabranched form and the antibacterial activity of the dendrimeric peptide showed to be much higher than that of the monomeric form. Modification of the original sequence, by residue substitution or sequence shortening, produced three different MAPs with enhanced stability to natural degradation and improved bactericidal activity against a large panel of Gram-negative bacteria. The same dendrimeric peptides showed high stability to blood proteases, low hemolytic activity and low cytotoxic effects on eukaryotic cells, making them promising candidates for the development of new antibacterial drugs.
The multivalency of peptide dendrimers appears to be desirable in the design of AMPs for their ability to amplify cationic charges and hydrophobic clusters as the number of dendrimer branches increases while the large hydrophobic core may enhance fusogenic activity. A plausible mechanism is that amplification by a dendrimeric design increases the local concentration of peptidic units mimicking the mechanisms of action through which high-ordered AMPs exert their membranolytic effects [144] . Synthesis of AMP in dendrimeric form may represent an unusual design but maybe a generally useful strategy for increasing their in vitro and in vivo activity.
Conclusions
During the past two decades it has become evident that increasing bacterial drug resistance has created an urgent need for new classes of antibiotics. Even if a superbug epidemic has not yet hit and the panel of traditional antibiotics can still manage drug resistant pathogens, at the moment, AMPs seem to represent one of the most promising future strategies for defeating this threat. This statement is well represented by the fact that AMPs are subject to an increasing number of academic studies. At industrial level, several companies worldwide are focused on the development of AMPs with several molecules both at the preclinical and clinical stage. This demonstrates that despite the first clinical trials failing (Pexiganan and Iseganan), there is still a lot of general optimism for their use in future clinical practice. Some of the challenges facing the development of peptidic drugs have already been overcome, starting from the industrial production of T-20 peptide (Fuzeon) at the multi-ton scale production, incredibly boosting the production of new peptides on a large scale with beneficial effects on the cost of all starting materials. Other challenges are common to other class of molecules that may be defined as innovative. Several strategies have been devised to optimize AMPs with promising activity, ranging from inclusion of non-natural aminoacids and a new method applicable to high-throughput screening to multimerization of linear sequences. Even if we cannot exclude the fact that resistance may evolve whenever bacterial populations are consistently exposed to elevated levels of AMPs, this concern should not discourage their further study and development; instead, they may help us to rationalize their use in future, for example preventing the big mistake made in the past of distribution of large amounts of antibiotics, and thereby minimizing the emergence of resistant organisms.
